目的：探讨醒脑静注射液联合纳络酮注射液在急性安定中毒治疗中的疗效。方法：本研究采用醒脑静注射液联合纳络酮注射液治疗急性安定中毒55例并与单纯纳络酮治疗的51例进行对照。106例患者均经静脉血毒物测定为安定中毒；来诊时均有意识障碍，平均年龄（30.35±7.95）合并酒精中毒及其他疾病20例，常规给予洗胃、补液、利尿促排泄、纠正电解质失衡、吸氧及抗感染等对症处理。结果：醒脑静注射液治疗组与对照组患者比较，神志恢复时间(h),治疗组(1.73±0.98)显著短于对照组(3.22±1.38)(P＜0.01)；同组患者就诊时与清醒后的神志、呼吸、血压、心率及瞳孔等临床指标比较差异有显著性(P＜0.05)。结论:醒脑静注射液与纳络酮联合应用，治疗急性安定中毒与对照组比较起效快、疗效确定，临床应用安全可靠。
Objective To determine whether Xingnaojing injection can improve functional outcome without causing harm in patients with intracerebral hemorrhage. Methods We searched the electronic bibl iographic databases: Cochrane Central Register of Controlled Trials(CENTRAL, Issue 3, 2007), MEDLINE (1996 to November 2007),EMBASE (1984 to November 2007) and China Biological Medicine Database (1978 to November 2007). We also did handsearching to identify other publ ished and unpubl ished data. Data were extracted and evaluated by two reviewers independently with a designed extraction form. The Cochrane Collaboration’s RevMan 4.2.10 was used for data analysis. Results Thirteen randomized trials involving 1 035 patients were included. The number of people who had died or were dependent at the end of long-term follow-up (at least 3 months) were reported in three trials. Eleven trials measured neurological deficit at the end of treatment. No severe adverse events were reported. The results of meta-analyses indicated that Xingnaojing injection might decrease the number of death or dependency compared to the control group, but the difference was not statistically significant (Peto-OR 0.57, 95％CI 0.32 to 1.01); and Xingnaojing injection were associated with a significant improvement in neurological deficit (Peto-OR 3.70, 95%CI 2.67 to 5.13). Conclusion The evidence currently available showed that Xingnaojing injection may decrease the risk of death or dependency, and can also reduce neurological deficit in patients with intracerebral hemorrhage. However, more high-qual ity trials are needed.